The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
No safety signals related to the vaccine candidate were identified
Offers affordable, high-quality solutions for diabetes care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
